US3689516A - Bis-carboxyethyl germanium sesquioxide and process for preparing same - Google Patents

Bis-carboxyethyl germanium sesquioxide and process for preparing same Download PDF

Info

Publication number
US3689516A
US3689516A US805370A US3689516DA US3689516A US 3689516 A US3689516 A US 3689516A US 805370 A US805370 A US 805370A US 3689516D A US3689516D A US 3689516DA US 3689516 A US3689516 A US 3689516A
Authority
US
United States
Prior art keywords
bis
germanium sesquioxide
trichlorogermanium
compound
carboxyethyl germanium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US805370A
Inventor
Kazuhiko Asai
Kazuo Makabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DAIICHI YAKUHIN SANGYO KK
Original Assignee
DAIICHI YAKUHIN SANGYO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DAIICHI YAKUHIN SANGYO KK filed Critical DAIICHI YAKUHIN SANGYO KK
Application granted granted Critical
Publication of US3689516A publication Critical patent/US3689516A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/30Germanium compounds

Definitions

  • the compound of the invention inhibits the proliferation of Ehrlich ascites tumor cells.
  • Germanium which has the atomic number of 32, is an atom having 32 electrons. Four of these electrons are located in an outer orbit and are unstable, being capable of separation from the rest under certain conditions. This property of germanium is utilized for transistors or diode rectifiers, as is popularly known. And there is a phenomenon that, when one of these four electrons has escaped, there results what is referred to as a positive hole of electric potential, to which other nearby electrons are drawn in. The composition of germanium being so, its organic compound is apt to cause electric charge transfer and to generate organic free radicals.
  • Applicants have for a long time studied the components of plant substances used for the so-called Chinese medical herbs, which have been known to be effective to check abnormal cells in the living body, and discovered that they contained a very large content of germanium, for example, 320 ppm in ginseng, 257 ppm in water-caltrop nut, 124 ppm in box-thorn nut, 108 ppm in wisteriaknot, 50 ppm in pearlbarley seed, 58 ppm in erythrorhizon, 76 ppm in comfry, and 756 ppm in garlic. This fact appears to indicate that germanium exists within these plants in the form of organic compounds.
  • B-cyanoethyltrichlorogermanium trichlorogermanium ethylene cyanide is obtained by the action of acrylonitrile on the known compound trichlorogermanium (germaniumchloroform).
  • B-Cyanoethyltrichlorogermanium is converted into B- trichlorogermanium propionic acid (trichlorogermanium propionic acid) by hydrolysis in the presence of a mineral acid and by the action of thionylchloride, this latter compound is converted to trichlorogermanium propionyl chloride. Hydrolysis of this compound with water produces bis-carboxylethyl germanium sesquioxide.
  • Test mice DD Shizuoka, 4 weeks old.
  • the administered group were very vigorous and had good appetite compared with the control group, showing no external appearance of reaction, the control group showed stagnant ascites whereas the administered group showed neither ascites stagnation nor bleeding, the proportion of the number of tumor cells in the bodies of the administered group was approximately 26 percent against percent in the bodies of the control group, and that there was a good indication of the effective checking of fissiparism.
  • the compound, bis-carboxyethyl germanium sesquioxide is a, are white, crystalline powder, and capable of polymerization on heating. Its melting point is impossible to measure, since heating to a higher temperature causes decomposition. In water solution, the oxygen in germanium sesquioxide is hydrated and the hydrogen stimulates charge transfer, thus causing activation. 7
  • the novel compound according to the present invention is of a very low order of toxicity.
  • the LD in mice as determined by hypodermic injection is 3,5g/kg of body weight.
  • the compound of the invention is soluble in water, and therefore it is most convenient to formulate it as solutions in sterile, pyrogen-free water, although any pharmaceutically acceptable carrier may be used.
  • a preferred therapeutic composition of the invention will comprise an aqueous solution containing from 0.01 to 0.4 by weight of the active ingredient.
  • compositions containing the compound according to the invention can be administered orally or Number of E.A.'I. Ascites amount, Aver- '1.I.,
  • Example l To 18 gr. of germaniumchloroform are added 6 gr. of acrylonitrile, and by heating under an atmosphere of 55 nitrogengas, Byanoethyltrichlorogermanium is obtained. This is converted to B-trichlorogermanium propionic acid by adding hydrochloric acid solution and heating. This is converted through reaction upon the dropwise addition of 12 gr. of thionylchloride, to trichlorogermanium propionyl chloride, which is recovered by distillation in vacuo. After complete hydrolysis takes place with water, bis-carboxyethyl germanium sesquioxide is obtained. This is washed with water until chlorine reaction disappears and a white powder is obtained. The yield is about 6 gr. Anal. calcd. for C,l-l ,O,(I1E Calculated value: 1 H2294, Ge:42.64 Found 113.00, Ge:42.41
  • the carrier can be a solid and in the form of a powder or tablet.
  • the solid carrier can be any of those commonly used in making medicinal formulations.

Abstract

The compound bis-carboxyethyl germanium sesquioxide is prepared as illustrated by the following equations:

Description

United States Patent Asai et al.
[ Sept. 5, 1972 [72] Inventors: Kazuhiko Asai, Tokyo-to; Kazuo Makabe, Kamakura-shi, both of Japan [73] Assignee: Daiichi Yakuhin Sangyo Kabushiki Kaisha, Tokyo-to, Japan [22] Filed: March 7, 1969 [21] Appl. No.: 805,370
[30] Foreign Application Priority Data March 29, 1968 Japan ..43/200s5 [52] US. Cl. ..260/429 R, 424/287 [51] Int. Cl. ..C07j 7/00, A6lk 27/00 [58] Field of Search ..260/429 [56] References Cited OTHER PUBLICATIONS Lesbre et al. Compt. Rend. Vol. 247 (1958) p. 471- Primary Examiner-Delbert E. Gantz Assistant ExaminerA. P. Dem'ers Attorney-Scrivener, Parker, Scrivener and Clarke ABSTRACT The compound bis-carboxyethyl germanium sesquioxide is prepared as illustrated by the following equations:
GeIIClg CIIgzCHCN Cl Gn-Cll Cll' CN Hydrolysis Cl3Ge-CII2CIIzCN ChGeCIhCIhCOOlI Hydrolysis 2C1; GeCHzCHzC 0 C1 This compound is effective for inhibiting the proliferation of Ehrlich ascites tumor cells.
2 Claims, No Drawings BIS-CARBOXYETI'IYL GERMANIUM SESQUIOXIDE AND PROCESS FOR PREPARING SAME DETAILED EXPLANATION OF THE INVENTION This invention relates to the compound bis-carboxyethyl germanium sesquioxide and having the following formula:
This is a compound and the invention also relates to a process of preparing it.
The compound of the invention inhibits the proliferation of Ehrlich ascites tumor cells.
It is believed that the mechanism by which the compound of the invention operates, is derived from the fact, already known, that the electric potential of abnormal cells in the living body is different from thatof normal cells.
Germanium, which has the atomic number of 32, is an atom having 32 electrons. Four of these electrons are located in an outer orbit and are unstable, being capable of separation from the rest under certain conditions. This property of germanium is utilized for transistors or diode rectifiers, as is popularly known. And there is a phenomenon that, when one of these four electrons has escaped, there results what is referred to as a positive hole of electric potential, to which other nearby electrons are drawn in. The composition of germanium being so, its organic compound is apt to cause electric charge transfer and to generate organic free radicals.
Applicants have for a long time studied the components of plant substances used for the so-called Chinese medical herbs, which have been known to be effective to check abnormal cells in the living body, and discovered that they contained a very large content of germanium, for example, 320 ppm in ginseng, 257 ppm in water-caltrop nut, 124 ppm in box-thorn nut, 108 ppm in wisteriaknot, 50 ppm in pearlbarley seed, 58 ppm in erythrorhizon, 76 ppm in comfry, and 756 ppm in garlic. This fact appears to indicate that germanium exists within these plants in the form of organic compounds.
The presence of this property of germanium and its peculiar characteristics previously described, led applicant to conclude that, if an organic germanium compound could be found that has the property to absorb a nearby electron, due to the escape of an electron resulting in a positive hole of electric potential, it could be utilized to change the electric potential of abnormal cells in the living body and to check their proliferation, it being known that the electric potential of abnormal cells is different from that of normal cells. Extensive research on the activities of various germanium compounds then followed. As a result, it was discovered that this activity is displayed by the compound of the invention, and this discovery led to the invention.
The process of making the compound according to the invention is as follows: B-cyanoethyltrichlorogermanium trichlorogermanium ethylene cyanide) is obtained by the action of acrylonitrile on the known compound trichlorogermanium (germaniumchloroform). B-Cyanoethyltrichlorogermanium is converted into B- trichlorogermanium propionic acid (trichlorogermanium propionic acid) by hydrolysis in the presence of a mineral acid and by the action of thionylchloride, this latter compound is converted to trichlorogermanium propionyl chloride. Hydrolysis of this compound with water produces bis-carboxylethyl germanium sesquioxide.
The described-process is illustrated by the following equations:
ChGOCHzCHgCOOH SOC]: Cl GeCH CHgCOOH O=GeCH2CHgCOOH Hydrol sis 2Cl GeCII CHgCOCl -r Bis-carboxyethyl germanium sesquioxide and, so produced, was tested on mice to which Ehrlich ascites tumor has been transplanted.
Test mice: DD Shizuoka, 4 weeks old.
Test procedure:
2,200,000 cells of Ehrlich ascites tumor, as the abnormal cells, were transplanted into the abdomen of mice. After 24 hours, 1 ml. of a sterile aqueous solution of 20 mcg of the compound of the present invention was injected into the abdomens of seven mice and a control into the abdomens of five of the mice. The injection was made every day for 7 days, and on the 8th day, dissection was conducted.
Examining the results, it is seen that the administered group were very vigorous and had good appetite compared with the control group, showing no external appearance of reaction, the control group showed stagnant ascites whereas the administered group showed neither ascites stagnation nor bleeding, the proportion of the number of tumor cells in the bodies of the administered group was approximately 26 percent against percent in the bodies of the control group, and that there was a good indication of the effective checking of fissiparism.
The compound, bis-carboxyethyl germanium sesquioxide is a, are white, crystalline powder, and capable of polymerization on heating. Its melting point is impossible to measure, since heating to a higher temperature causes decomposition. In water solution, the oxygen in germanium sesquioxide is hydrated and the hydrogen stimulates charge transfer, thus causing activation. 7
The novel compound according to the present invention is of a very low order of toxicity. The LD in mice as determined by hypodermic injection is 3,5g/kg of body weight.
The compound of the invention is soluble in water, and therefore it is most convenient to formulate it as solutions in sterile, pyrogen-free water, although any pharmaceutically acceptable carrier may be used.
A preferred therapeutic composition of the invention will comprise an aqueous solution containing from 0.01 to 0.4 by weight of the active ingredient.
Compositions containing the compound according to the invention can be administered orally or Number of E.A.'I. Ascites amount, Aver- '1.I.,
Total age percent Summary TABLE Weight Just be- Third Sixth fore dising day day section ml. Unit Mouse Startnumber X X L are 1 +1.). 1. 1 +L+1+++ i 1111 +0 dfiadfi n n i zuu ..(,.l .(E.( g nnmwdfi 3 0M .123 1 1111 3. .11.). 110%. ++d+ d (.m dd wsdd m M m W+ mi w a w ++H+ eeh++ d md d+ d+ no 2+ H H e 1 e T T n P m d Ham WDH @(G 0.0%WH 11. 1 H .20.. 11111 ++M mmTTmTr +r+r r immim m ++TTT \J A11 A v e s s 1 1 a n 111 001 12 .1 .1111 fiififii fiafia H 11 h 1 1. 1 1 1 0 w EEEEEEE E(E(E W(EE(EE( ((EEE wwwwwww .1. m 1 ..1..1..1..1,.1:1.1. L nmr ur nrnnr 1 1 1 SSSSSSS AA WW m m n 1 1 .SSQ WWWWW V W WW 1.111.111 11 1 1. m m mwfinmw mm mmmm mwmmwmm Mmwmm H 0 S [l 1 P wi ll a m a 1 m m a e m 2 m 1% a a W L 1 W W 2 4 m 3 9 H 1 w M 7 m 7 E 1. d a E W i w m i w a 2 4 e w 4 3 4 0 7. W W 1 2 W M To" m 7 4 00 0 0 V 4 8 1 21 wwww wm wmmmmmw m mm i w w w m 72 6 7 1 1 5 :1. e i i i ii. 1 4528 2 E l 4 25 no" H W W M O m 0m00000 OTW O W 00000 w +w w w 2 0 W 4 W mm%m% 80m5006 9 8722 47 .m 1 .M H .m U WM m 435-WvH6J0 m m m n o i 1 X M m N t 6818722 4877880 0057808 71471 .11 .1 1. w u m .m 11 1 1102100 1 5 0 1 3 m o. w e E u m m H w m m T 5005373 50550? 20520 e m m 11 2100 11121 01 001 2110 L5 0 L3 0 S0 0.0.00.0.00 20551 W m 5 Am 1 11001 ++01+ 1 h m a 1 e .10. W S. 9 7++ I t 12 1 1 :1 v 50 0 S "4 g +1 0 1 r m n Mum 0 505 0 5002545 3355403 551 m 0 23 2 1 w m mwm 1 110 2 +1+ ++&++ ++0 1+ 12 1 2 m m w m m 1 0 0 ++0 0 o 5 0 +o 5 0 5 5 0 ++0 H and .1... w m .5. 30.23 0 1 3 2% 2 1 12 22 0 3 0 S r 2 0Rwflw0m w9 4 m a m 2212111 2% n m 2 m 0 0 90 0 0 5 H r M h 0 3 50126 55 04550 du fl 22121 w o d .1 ma 1 2u122o ++L+++ L21o 1 +d+a 2 2 2 m m m n h s n++ 5 1 0 20 0 ;m0 a 0 +5 0 00500 00655 m M m m 0 010 0 5 ammaminwii 0 5 0 2190.002 0 c 2212122 t W W mmm H 1 m 1 I a 1 0b dv. 0500500 0 05505 0505500 00555 505500 I m lo( ha 1 Lnwowowomomm MMM MN M u mm d flmwwwwfl WEED mm mflmflflmm mmmmwm 221111 mN m e m T 150. N ww m 505 50 5000500 5050505 50550 1234507 23456 5 O LO-9990 22222 W Fr. 221111 9 mmmmwmwm wmw2mmfl N m t n hfl .1 L m 12345 6 89 i ll m mflm mr 67 m REM w flllmm H%M%% m km U0 MW =Ec N lill u il i i Y S v 1 X H e T .T 1 m mm w h H r ix m L MA o m l av n.m r M H m "w ma T 1b] t Bem 0 lmmmw m B C Kdnu A B C 0 One millilitre of physiological salt water.
Example l: To 18 gr. of germaniumchloroform are added 6 gr. of acrylonitrile, and by heating under an atmosphere of 55 nitrogengas, Byanoethyltrichlorogermanium is obtained. This is converted to B-trichlorogermanium propionic acid by adding hydrochloric acid solution and heating. This is converted through reaction upon the dropwise addition of 12 gr. of thionylchloride, to trichlorogermanium propionyl chloride, which is recovered by distillation in vacuo. After complete hydrolysis takes place with water, bis-carboxyethyl germanium sesquioxide is obtained. This is washed with water until chlorine reaction disappears and a white powder is obtained. The yield is about 6 gr. Anal. calcd. for C,l-l ,O,(I1E Calculated value: 1 H2294, Ge:42.64 Found 113.00, Ge:42.41
Notes.-Deg.=Degeneration degree; PSW 1= It has been observed that chemical reaction involving the compounds of the invention occurin the body only The following examples will serve to illustrate the preparation of the compounds of the present invention but are not to be construed as limiting in nature.
parenterally by intramuscular or intravenous injection. Also, if the diseased area is defined by a body cavity, the aqueous solution can be applied directly to the diseased area as by a catheter or irrigation. If administration is to be by the oral route, the carrier can be a solid and in the form of a powder or tablet. The solid carrier can be any of those commonly used in making medicinal formulations.
at the site of abnormal cells, and this is believed to give credence to the theory set forth above.
What is claimed is: i l. Bis-carboxyethyl germanium sesquioxide, of the formula O=GcCllzCllgC0Oll O=( eOH:CII2COOH 2. A process of producing bis-carboxyethyl germanium sesquioxide, comprising reacting germaniumchloroform with acrylonitrile to produce B-

Claims (1)

  1. 2. A process of producing bis-carboxyethyl germanium sesquioxide, comprising reacting germaniumchloroform with acrylonitrile to produce B-cyanoethyltrichlorogermanium; hydrolyzing B--cyanoethyltrichlorogermanium in the presence of a mineral acid to produce B-trichlorogermanium propionic acid; reacting B-trichlorogermanium propionic acid with thionyl chloride to produce trichlorogermanium propionyl chloride; and hydrolyzing trichlorogermanium propionyl chloride to obtain bis-carboxyethyl germanium sesquioxide.
US805370A 1968-03-29 1969-03-07 Bis-carboxyethyl germanium sesquioxide and process for preparing same Expired - Lifetime US3689516A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008568 1968-03-29

Publications (1)

Publication Number Publication Date
US3689516A true US3689516A (en) 1972-09-05

Family

ID=12017251

Family Applications (1)

Application Number Title Priority Date Filing Date
US805370A Expired - Lifetime US3689516A (en) 1968-03-29 1969-03-07 Bis-carboxyethyl germanium sesquioxide and process for preparing same

Country Status (7)

Country Link
US (1) US3689516A (en)
BE (1) BE730615A (en)
CH (1) CH521376A (en)
DE (1) DE1793288B1 (en)
FR (1) FR2005110A1 (en)
GB (1) GB1257225A (en)
NL (1) NL6904836A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066678A (en) * 1975-10-23 1978-01-03 Ryuichi Sato 3-trihydroxygermyl propionic acid and its salts and a process for the production thereof
US4271084A (en) * 1978-03-01 1981-06-02 Ryuichi Sato Germanium-containing organic polymer and the process for the production of the same
US4361579A (en) * 1979-09-19 1982-11-30 Yoshitomi Pharmaceutical Industries, Ltd. Organogermanium compounds
EP0085513A1 (en) * 1982-02-01 1983-08-10 Industrial Technology Research Institute Method for preparing organo germanium propionic acid derivatives
US4508654A (en) * 1982-02-01 1985-04-02 Industrial Technology Research Institute Preparation of bis-carboxy ethyl germanium sesquioxide and its propionic acid derivatives
DE3514659A1 (en) * 1984-04-25 1985-10-31 Asai Germanium Research Institute, Tokio/Tokyo ANTIOXIDANT
US4579961A (en) * 1982-08-23 1986-04-01 Norihiro Kakimoto Organogermanium compounds having both hydrophilicity and lipophilicity and process for producing the same
US4956272A (en) * 1987-10-29 1990-09-11 Asai Germanium Research Institute Co., Ltd. Organogermanium containing solution for washing and storing separated organs
US5006553A (en) * 1987-10-29 1991-04-09 Asai Germanium Research Institute Co., Ltd. Agent for improving reduced functions of organs caused by inhibited blood circulation

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3812167A (en) * 1971-08-27 1974-05-21 Pahk Heart Foundation Germanium derivative
JPS5473129A (en) * 1977-11-22 1979-06-12 Asai Germanium Res Inst External skin remedy
JPS55122717A (en) * 1979-03-15 1980-09-20 Asai Gerumaniumu Kenkyusho:Kk Interferon inducer
JPS6016924A (en) * 1983-07-11 1985-01-28 Asai Gerumaniumu Kenkyusho:Kk Antineoplastic agent
JP2698870B2 (en) * 1987-10-29 1998-01-19 株式会社浅井ゲルマニウム研究所 Agent for reducing nephrotoxicity by administration of cyclosporine
EP0404062A3 (en) * 1989-06-20 1991-09-25 Sanwa Kagaku Kenkyusho Co., Ltd. Organogermanium compound, process for preparation of same as well as use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lesbre et al. Compt. Rend. Vol. 247 (1958) p. 471 474 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066678A (en) * 1975-10-23 1978-01-03 Ryuichi Sato 3-trihydroxygermyl propionic acid and its salts and a process for the production thereof
US4271084A (en) * 1978-03-01 1981-06-02 Ryuichi Sato Germanium-containing organic polymer and the process for the production of the same
US4361579A (en) * 1979-09-19 1982-11-30 Yoshitomi Pharmaceutical Industries, Ltd. Organogermanium compounds
EP0085513A1 (en) * 1982-02-01 1983-08-10 Industrial Technology Research Institute Method for preparing organo germanium propionic acid derivatives
US4420430A (en) * 1982-02-01 1983-12-13 Industrial Technology Research Institute Method for preparing organo germanium propionic acid derivatives
US4508654A (en) * 1982-02-01 1985-04-02 Industrial Technology Research Institute Preparation of bis-carboxy ethyl germanium sesquioxide and its propionic acid derivatives
US4579961A (en) * 1982-08-23 1986-04-01 Norihiro Kakimoto Organogermanium compounds having both hydrophilicity and lipophilicity and process for producing the same
DE3514659A1 (en) * 1984-04-25 1985-10-31 Asai Germanium Research Institute, Tokio/Tokyo ANTIOXIDANT
US4720564A (en) * 1984-04-25 1988-01-19 Asai Germanium Research Institute Antioxidant organogermanium compound
US4956272A (en) * 1987-10-29 1990-09-11 Asai Germanium Research Institute Co., Ltd. Organogermanium containing solution for washing and storing separated organs
US5006553A (en) * 1987-10-29 1991-04-09 Asai Germanium Research Institute Co., Ltd. Agent for improving reduced functions of organs caused by inhibited blood circulation

Also Published As

Publication number Publication date
BE730615A (en) 1969-09-01
CH521376A (en) 1972-04-15
FR2005110A1 (en) 1969-12-05
NL6904836A (en) 1969-10-01
DE1793288B1 (en) 1971-05-27
GB1257225A (en) 1971-12-15

Similar Documents

Publication Publication Date Title
US3689516A (en) Bis-carboxyethyl germanium sesquioxide and process for preparing same
Storer et al. Protective effect of para-aminopropiophenone against lethal doses of X-radiation
EP0324154A2 (en) 1,2 Bis(aminomethyl)cyclobutane-platinum-complexes
LU83982A1 (en) PLATIN-DIAMINE COMPLEXES, A METHOD FOR THE PRODUCTION THEREOF, A METHOD FOR THE PRODUCTION OF A MEDICINAL PRODUCT USING SUCH A PLATIN-DIAMINE COMPLEX FOR THIS TREATMENT OF CANCER AND THE ARMY OBTAINED THEREOF
EP0552240A1 (en) New method of treating depression
US4892735A (en) Platinum chemotherapeutic product
US2761807A (en) Glycocyamine and methylating agent in vivo creatine producing composition
US2561468A (en) p-n-mono- and disubstituted aminohydroxyalkylbenzoates and processes of producing same
US3988461A (en) Pharmaceutical composition for the treatment of Parkinson's disease
DE3424107A1 (en) ORGANOGERMANIUM COMPOUND AND THIS ACTIVE INGREDIENT OPIOID PEPTIDAS INHIBITOR
US2781291A (en) Magnesium chelate of ethylenediaminetetraacetic acid for treatment of hypertension
US2507468A (en) Monobasic phosphate of 1-phenyl-2-aminopropane
US2939817A (en) Method of treating diseases associated with plasmin activity
DE3011274A1 (en) SYNERGISTIC RADIATION PROTECTIVE PHARMACEUTICAL PREPARATIONS AND THEIR PRODUCTION
US4241084A (en) Antibacterial and antifungal compositions
US3439091A (en) Method of treatment with modified tetracycline compounds and composition therefor
GB1272337A (en) New basic carbamates and preparation thereof
FR2677650B1 (en) RETINOUIDES SUBSTITUTED BY A DITHIAN CYCLE AND THEIR USE, PROCESS FOR PREPARING THE SAME, COSMETIC AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THERAPEUTIC USE THEREOF.
US3196076A (en) Anti-depressant 10-(3-dimethylaminopropyl)-3-azaphenothiazine
DE2924077C2 (en)
US3436458A (en) Antispasmodic and gastric antisecretory compositions containing rho-phenylphenacyl derivatives of 1-hyoscyamine and d,1-tropylatropine
CA1155395A (en) Pharmaceutical composition having normolipidemic and platelet anti-binding activity
Hunt Notes on Acetyl-Methyl-Choline
US2851393A (en) Beta-diethylamino butyric acid anilide, nontoxic salts thereof and aqueous local anesthetic solutions therewith
US3655892A (en) Pharmaceutical preparations and methods of using same